{"id":"W4402388619","doi":"10.1016/s1470-2045(24)00402-9","title":"[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Health and Medical Research Council; Astellas Pharma; Ipsen; National Breast Cancer Foundation; Y-mAbs Therapeutics; Exelixis; Australian and New Zealand Society of Nuclear Medicine; Actinium Pharmaceuticals; Pfizer; Intuitive Surgical; Australian Cancer Research Foundation; Regeneron Pharmaceuticals; Veracyte; Verily Life Sciences; Society of Nuclear Medicine and Molecular Imaging; National Imaging Facility; Medical Research Council; Australian Nuclear Science and Technology Organisation; U.S. Department of Justice; Bristol-Myers Squibb; Progenics Pharmaceuticals","keywords":"Open label; Renal cell carcinoma; Medicine; Nuclear medicine; Oncology; Clinical trial; Internal medicine","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005854224,0.001901753,0.002330428,0.0005434438,0.0005432754,0.001499306,0.001123025,0.001958745,0.001982023],"category_scores_gemma":[0.001705717,0.0007844936,0.00190624,0.0007106432,0.001717112,0.001155922,0.0005846756,0.002462756,0.0006510138],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001276004,"about_ca_system_score_gemma":0.002066894,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001385429,"about_ca_topic_score_gemma":0.002602253,"domain_scores_codex":[0.9983145,0.0009776695,0.00008143389,0.0002449195,0.0001432001,0.0002383903],"domain_scores_gemma":[0.9987764,0.00017949,0.0003725062,0.0001424521,0.0001214857,0.0004076913],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9133104,0.02148764,0.006201359,0.0007205413,0.001405181,0.0001711787,0.0002855561,0.001648751,0.02565859,0.0001970366,0.0009946148,0.02791917],"study_design_scores_gemma":[0.6525284,0.3308603,0.01106983,0.00003353052,0.0006901566,0.000208909,0.00006997782,0.0008056085,0.00183585,0.0001572447,0.001704703,0.00003540758],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9881625,0.003259417,0.0009758858,0.0003148128,0.0001202284,0.005618367,0.0005988968,0.00008108836,0.0008688529],"genre_scores_gemma":[0.9873016,0.001973783,0.002881328,0.000822641,0.0001638163,0.004615487,0.001320539,0.00003548768,0.000885308],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005854224,"threshold_uncertainty_score":0.03096044,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07505544025566038,"score_gpt":0.3864743047778392,"score_spread":0.3114188645221788,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}